267 related articles for article (PubMed ID: 31821048)
1. Modulation of expression/function of intestinal P-glycoprotein under disease states.
Murakami T; Bodor E; Bodor N
Expert Opin Drug Metab Toxicol; 2020 Jan; 16(1):59-78. PubMed ID: 31821048
[No Abstract] [Full Text] [Related]
2. Factors and dosage formulations affecting the solubility and bioavailability of P-glycoprotein substrate drugs.
Murakami T; Bodor E; Bodor N
Expert Opin Drug Metab Toxicol; 2021 May; 17(5):555-580. PubMed ID: 33703995
[No Abstract] [Full Text] [Related]
3. Evaluation of the Role of P-glycoprotein (P-gp)-Mediated Efflux in the Intestinal Absorption of Common Substrates with Elacridar, a P-gp Inhibitor, in Rats.
Suzuki K; Taniyama K; Aoyama T; Watanabe Y
Eur J Drug Metab Pharmacokinet; 2020 Jun; 45(3):385-392. PubMed ID: 32078103
[TBL] [Abstract][Full Text] [Related]
4. Predicting drug-drug interactions involving the inhibition of intestinal CYP3A4 and P-glycoprotein.
Tachibana T; Kato M; Takano J; Sugiyama Y
Curr Drug Metab; 2010 Nov; 11(9):762-77. PubMed ID: 21189139
[TBL] [Abstract][Full Text] [Related]
5. Intestinal transporters: enhanced absorption through P-glycoprotein-related drug interactions.
Zakeri-Milani P; Valizadeh H
Expert Opin Drug Metab Toxicol; 2014 Jun; 10(6):859-71. PubMed ID: 24708201
[TBL] [Abstract][Full Text] [Related]
6. Quantitative evaluation of the function of small intestinal P-glycoprotein: comparative studies between in situ and in vitro.
Adachi Y; Suzuki H; Sugiyama Y
Pharm Res; 2003 Aug; 20(8):1163-9. PubMed ID: 12948013
[TBL] [Abstract][Full Text] [Related]
7. Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs.
Patel J; Mitra AK
Pharmacogenomics; 2001 Nov; 2(4):401-15. PubMed ID: 11722289
[TBL] [Abstract][Full Text] [Related]
8. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.
Darwich AS; Neuhoff S; Jamei M; Rostami-Hodjegan A
Curr Drug Metab; 2010 Nov; 11(9):716-29. PubMed ID: 21189140
[TBL] [Abstract][Full Text] [Related]
9. Prediction of Atorvastatin Pharmacokinetics in High-Fat Diet and Low-Dose Streptozotocin-Induced Diabetic Rats Using a Semiphysiologically Based Pharmacokinetic Model Involving Both Enzymes and Transporters.
Wang Z; Yang H; Xu J; Zhao K; Chen Y; Liang L; Li P; Chen N; Geng D; Zhang X; Liu X; Liu L
Drug Metab Dispos; 2019 Oct; 47(10):1066-1079. PubMed ID: 31399507
[TBL] [Abstract][Full Text] [Related]
10. Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass.
Bruyère A; Declèves X; Bouzom F; Ball K; Marques C; Treton X; Pocard M; Valleur P; Bouhnik Y; Panis Y; Scherrmann JM; Mouly S
Mol Pharm; 2010 Oct; 7(5):1596-607. PubMed ID: 20604570
[TBL] [Abstract][Full Text] [Related]
11. The pharmacological role of P-glycoprotein in the intestinal epithelium.
Van Asperen J; Van Tellingen O; Beijnen JH
Pharmacol Res; 1998 Jun; 37(6):429-35. PubMed ID: 9695116
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic analysis for drug permeation through intestinal membrane.
Hayashi M; Tomita M
Drug Metab Pharmacokinet; 2007 Apr; 22(2):67-77. PubMed ID: 17495413
[TBL] [Abstract][Full Text] [Related]
13. Baicalin reduces ciclosporin bioavailability by inducing intestinal p-glycoprotein in rats.
Tian X; Chang Y; Wei J; Liu R; Wang L; Zhang J; Zhang X
J Pharm Pharmacol; 2019 May; 71(5):788-796. PubMed ID: 30663770
[TBL] [Abstract][Full Text] [Related]
14. Crohn's Disease Is Associated with Decreased CYP3A4 and P-Glycoprotein Protein Expression.
Wilson A; Urquhart BL; Ponich T; Chande N; Gregor JC; Beaton M; Kim RB
Mol Pharm; 2019 Sep; 16(9):4059-4064. PubMed ID: 31393129
[TBL] [Abstract][Full Text] [Related]
15. Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium.
Troutman MD; Thakker DR
Pharm Res; 2003 Aug; 20(8):1210-24. PubMed ID: 12948019
[TBL] [Abstract][Full Text] [Related]
16. Impact of inflammation on the duodenal mRNA expression of CYP3A and P-glycoprotein in children with Crohn's disease.
Fakhoury M; Lecordier J; Medard Y; Peuchmaur M; Jacqz-Agrain E
Inflamm Bowel Dis; 2006 Aug; 12(8):745-9. PubMed ID: 16917230
[TBL] [Abstract][Full Text] [Related]
17. Intestinal efflux transporters and drug absorption.
Murakami T; Takano M
Expert Opin Drug Metab Toxicol; 2008 Jul; 4(7):923-39. PubMed ID: 18624680
[TBL] [Abstract][Full Text] [Related]
18. Functional alterations of intestinal P-glycoprotein under diabetic conditions.
Kobori T; Harada S; Nakamoto K; Tokuyama S
Biol Pharm Bull; 2013; 36(9):1381-90. PubMed ID: 23995645
[TBL] [Abstract][Full Text] [Related]
19. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein.
Zhang Y; Benet LZ
Clin Pharmacokinet; 2001; 40(3):159-68. PubMed ID: 11327196
[TBL] [Abstract][Full Text] [Related]
20. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
